Aoxing Pharmaceutical Company, Inc.
AOXG · OTC
6/30/2025 | 6/30/2024 | 6/30/2016 | 6/30/2015 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $32,330 | $25,481 |
| % Growth | – | -100% | 26.9% | – |
| Cost of Goods Sold | $0 | $0 | $7,776 | $5,689 |
| Gross Profit | $0 | $0 | $24,554 | $19,792 |
| % Margin | – | – | 75.9% | 77.7% |
| R&D Expenses | $0 | $0 | $3,143 | $337 |
| G&A Expenses | $0 | $0 | $3,067 | $2,754 |
| SG&A Expenses | $7 | $15 | $14,680 | $10,211 |
| Sales & Mktg Exp. | $0 | $0 | $11,613 | $7,458 |
| Other Operating Expenses | $0 | $0 | $202 | $0 |
| Operating Expenses | $7 | $15 | $18,326 | $11,097 |
| Operating Income | -$7 | -$15 | $6,228 | $8,696 |
| % Margin | – | – | 19.3% | 34.1% |
| Other Income/Exp. Net | $63 | -$0 | -$3,342 | -$5,582 |
| Pre-Tax Income | $55 | -$15 | $2,886 | $3,114 |
| Tax Expense | $0 | $0 | $642 | -$2,704 |
| Net Income | $55 | -$15 | $2,061 | $5,495 |
| % Margin | – | – | 6.4% | 21.6% |
| EPS | 0 | -0 | 0.03 | 0.09 |
| % Growth | 330.2% | -100.1% | -66.7% | – |
| EPS Diluted | 0 | -0 | 0.03 | 0.09 |
| Weighted Avg Shares Out | 381,209 | 341,209 | 73,695 | 63,107 |
| Weighted Avg Shares Out Dil | 381,209 | 341,209 | 75,468 | 63,167 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $3,457 | $5,768 |
| Depreciation & Amortization | $0 | $168 | $1,026 | $666 |
| EBITDA | $55 | -$15 | $7,254 | $9,362 |
| % Margin | – | – | 22.4% | 36.7% |